Mucopolysaccharidoses and oligosaccharidoses

Inborn Metabolic Diseases: Diagnosis and Treatment

Volumn , Issue , 2012, Pages 579-590

  Wraith, J Ed ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890689616     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-15720-2_40     Document Type: Chapter

References (30)

1. Cleary MA, Wraith JE (1995) The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr Scand 84:337-339
2. Cleary MA, Wraith JE (1993) Management of mucopolysaccharidosis type III. Arch Dis Child 69:403-406
3. Natowicz MR, Short MP, Wang Y et al. (1996) Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med 335:1029-1033
4. Triggs-Raine B, Salo TJ, Zhang H et al. (1999) Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci USA 96:6296-6300
5. Imundo L, Luduc CA, Guha S et al (2011). A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopatic arthritis. J Inherit Metab Dis. 2011 Oct;34:1013-22
6. Malm D, Halvorsen DS, Tranebjaerg L et al. (2000) Immunodeficiency in alpha-mannosidosis: a matched case-control study on immunoglobulins, complement factors, receptor density, phagocytosis and intracellular killing in leucocytes. Eur J Pediatr 159:699-703
7. Bedilu R, Nummy KA, Cooper A et al. (2002) Variable clinical presentation of lysosomal beta-mannosidosis in patients with null mutations. Mol Genet Metab 77:282-290
8. Willems PJ, Gatti R, Darby JK et al. (1991) Fucosidosis revisited: a review of 77 patients. Am J Med Genet 38:111-131
9. Kleta R, Morse RP, Orvisky E et al. (2004) Clinical, biochemical, and molecular diagnosis of a free sialic acid storage disease patient of moderate severity. Mol Genet Metab 82:137-143
10. Mochel F, Yang B, Barritault J et al. (2009) Free sialic acid storage disease without sialuria. Ann Neurol 65:753-757
11. Mochel F, Sedel F, Vanderver A et al. (2009) Cerebellar ataxia with elevated cerbrospinal free sialic acid (CAFSA). Brain 132:801-809
12. Arvio MA, Peippo MM, Arvio PJ et al. (2004) Dysmorphic facial features in aspartylglucosaminuria patients and carriers. Clin Dysmorphol 13:11-15
13. Arvio M (1993) Follow-up in patients with aspartylglucosaminuria. Part I. The course of intellectual functions. Acta Paediatr Scand 82:469-471
14. Sakuraba H, Matsuzawa F, Aikawa S et al. (2004) Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet 49:1-8
15. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238
16. Malvagia S, Morrone A, Caciotti A et al. (2004) New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor. Mol Genet Metab 82:48-55
17. Walkley SU (2009) Pathogenic cascades in lysosomal disease – why so complex? J Inherit Metab Dis 32:181-189
18. Zhang XK, Elbin CS, Chuang WL et al. (2008) Multiple enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrotomy. Clin Chem 54:1725-1728
19. Rothenbuhler A, Piquard C, Gueorguieva I et al (2010) Near normalization of adult height and body proportions by growth hormone in pycnodysostosis. J Clin Endocrinol Metab 95:2827-2828
20. Malinowska M, Wilkinson FL, Bennett W et al. (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharidosis type IIIB mice. Mol Genet Metab 98:235-242
21. Prasad VK, Kurtzberg J (2010) Transplant outcomes in mucopolysaccharidoses. Semin Hematol 47:59-69
22. Weisstein JS, Delgado E, Steinbach LS et al. (2004) Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24:97-101
23. Sifuentes M, Doroshow R, Holt R et al. (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171-180
24. Wynn RF, Mercer J, Carr TF et al. (2009) Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr 154:135-139
25. Muenzer J, Wraith JE, Beck M et al. (2006) A phase II/III clinical study of enzyme replacement therapy with Idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465-473
26. Harmatz P, Gugliani R, Schwartz IV et al. (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94: 469-475
27. Wraith JE (2006) Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis 29:422-447
28. Dicksion PI (2009) Novel treatments and future perspectives: outcome of intrathecal drug delivery. Int J Clin Pharmacol Ther 47 [Suppl 1]: S124-S127
29. Schiffmann R (2010) Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis 33:373-9
30. Haskins M (2009) Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 50: 112-121